JAN News and Press, JanOne Inc. From 11/13/23

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

2023-11-09 08:52:54 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Assertio (NASDAQ: ASRT ) stock is diving lower on Thursday after the commercial pharmaceutical company released its earnings report for the third quarter of 2023 . The bad n...

2023-11-09 08:23:49 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Atara Biotherapeutics (NASDAQ: ATRA ) stock is falling hard on Thursday after the therapeutics company announced results from a Phase 2 clinical trial . The bad news for...

2023-11-09 08:05:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips JanOne (NASDAQ: JAN ) stock is on the rise Thursday despite a lack of news from the clinical-stage biopharmaceutical company . There haven’t been any news press relea...

2023-11-09 07:30:35 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s time to start the day with a breakdown of the biggest pre-market stock movers worth keeping tabs on for Thursday! Earnings reports continue to be a major catalyst for stocks thi...

JanOne to Present at the Dawson James 8th Annual Investment Conference PR Newswire Chief Medical Officer Dr. Amol Soin will explain innovative approaches to pain management and JanOne's development of non-addicting treatments for pain LAS VEGAS , Sept. 21...

JUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8 th Annual Dawson James Small Cap Growth Conferen...

JanOne to Present In Person and by Video at H.C. Wainwright's 25th Annual Global Investment Conference PR Newswire Chief Medical Officer Dr. Amol Soin will discuss innovative approaches to pain management and JanOne's development of non-addicting treatments for pain ...

JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic Pain PR Newswire The Broad Patent Coverage is a Major Milestone for the Commercial Success of Jan123 LAS VEGAS , Aug. 29, 2023 /PRNewswire/ -- Jan...

JanOne Wins "Best Abstract" Award at the Ohio Society of Interventional Pain Physicians Annual Meeting PR Newswire Abstract explained Jan101's statistically significant reduction in pain and improvement in nerve conduction velocity in prior Phase II study. LAS VEGAS ...